Findings showed blarcamesine patients had a 36.3% reduction in clinical decline based on ADAS-Cog13 scores compared with placebo at 48 weeks. Blarcamesine significantly slowed cognitive decline in ...

In that consent decree, the VA vowed to automatically reconsider past denials of benefits for conditions that it later found were tied to Agent Orange and to grant retroactive benefits. Used ...

Kinnaird’s clients sued the government in 1986 for denying claims for benefits based on diseases that it subsequently found were tied to exposure to the toxic contaminant dioxin in Agent Orange, an ...